Newsletter I N T H I S I S S U E
|
|
- Shana Evans
- 6 years ago
- Views:
Transcription
1 V O L U M E 1 1. I S S U E NEWS THAT MATTERS TO HOSPICE Making Management of Opioid-Induced Constipation a Smooth Move Heidi Trautwein, RPh, PharmD, CGP, FASCP, Clinical Pharmacist, HospiScript Constipation can be one of the most distressing symptoms for a hospice patient, and with approximately 50% of patients experiencing constipation, this symptom should not be overlooked. 1 Have you noticed the multitude of prescription medications for opioid-induced constipation? Ever wonder what to use first? Let s review opioid-induced constipation and explore the role of laxatives in hospice symptom management. Constipation can contribute to delirium, abdominal pain and distension, and embarrassment. Frequent assessment of bowel function and use of preventative interventions is imperative for patients receiving hospice care. Assess the patient s normal bowel habits and any complications of constipation such as agitation, anorexia, confusion, nausea, pain, and urinary dysfunction on admission and regularly throughout care. 1,2 Patients with constipation may present with abdominal tenderness, bloating, flatulence, and the feeling of incomplete evacuation. 1,2 In addition to discussing symptoms and normal bowel habits with a patient, a physical assessment including listening to bowel sounds, palpating the abdomen, and examining the rectal vault are also important assessment tools in managing constipation. 1,2 The Bristol Stool Scale describes seven types of feces and is a tool for assessing intestinal transit time and changes in stool consistency. 3 This scale can be used to assess severity of constipation. Several factors contribute to constipation including dehydration, immobility, reduced food and fluid intake, and medications (Table 2). 4 Opioids are likely the most prevalent medication-related cause of constipation in the hospice setting. To understand how to treat opioid-induced constipation (OIC), we must first understand how opioids cause constipation. Opioids provide analgesia through activation of the µ-opioid receptors in the central nervous system (CNS) which is comprised of the brain and spinal cord; however, they also exert their effects on peripheral µ-opioid receptors including those in the gastrointestinal (GI) tract. Activation of µ-opioid receptors in the GI tract reduces fluid secretion and H O S P I S C R I P T N E W S L E T T E R V O L U M E 1 1. I S S U E increases water absorption from the colon resulting in hardened stool. Large intestine µ-opioid receptor activation also leads to reduced peristalsis of the bowel. 5 Reduction in GI motility results in hardened stool in up to 90% of patients taking opioids. 1 Prophylactic treatment for OIC should start at initiation of opioid therapy and continue throughout treatment with opioids. Fiber supplements such as psyllium (Metamucil ), polycarbophil (FiberCon ), methylcellulose (Citrucel ) are not recommended for use in patients with OIC. Avoid fiber supplements in OIC due to increased risk of fecal impaction. Other over-the-counter (OTC) medications for constipation are effective and the first step in managing constipation. The gold standard for treating OIC is a combination of stimulant laxative and stool softener such as Senna-S. Senna-S may be titrated to a max dose of 8 tablets per day to manage symptoms. 1 The least invasive route of administration (oral) is recommended however, if swallowing is impaired; bisacodyl rectal suppositories can be an effective alternative to oral stimulant laxatives. For a patient who desires a chewable product, chocolate sennoside tablets (Ex-Lax Chocolate) may be useful in managing symptoms. Once stimulant laxatives are optimized, the addition of an osmotic laxative may be effective in managing symptoms. Osmotic laxatives cause water retention in the stool resulting in increased frequency of bowel movements. Of the osmotic laxatives, sorbitol is more cost effective than lactulose; however, patients may not find either of these palatable in higher doses. Polyethylene glycol 3350 (Miralax ) is a flavorless osmotic laxative, that is mixed in 4-8 ounces of juice, tea or other fluids of patient preference. 6 The fluid Table 1: Bristol Stool Scale 3 STOOL TYPE STOOL DESCRIPTION Continued on page 2 1 Separate hard lumps, like nuts.* 2 Sausage shaped but lumpy.* 3 Like a sausage or snake but with cracks on its surface. 4 Like a sausage or snake, smooth and soft. 5 Soft blobs with clear cut edges. 6 Fluffy pieces with ragged edges, a mushy stool. 7 Watery, no solid pieces. * Type 1 and 2 may indicate constipation EMPOWERING HOSPICE CARE THROUGH INNOVATION TM Newsletter I N T H I S I S S U E Making Management of Opioid-Induced Constipation a Smooth Move Clinical Case Study: Opioid-Induced Constipation In The Spotlight It s Here: 4th Edition Palliative Care Consultant HospiMobile TM 2.0 HospiScript Regional Conference Savannah, GA May 14-15, 2015 Lunch & Learn Teleconferences Register Online! Clinician s Corner: Hospice Item Set (HIS): NQF 1617 Patients Treated with an Opioid who are Given a Bowel Regimen On a Lighter Note Ask HospiScript Sharing information and updates about the HospiScript program The HospiScript Newsletter is a quarterly publication for the clients of HospiScript Services. Articles for publication consideration may be submitted to the attention of the Managing Editor, Kim Konczal (kkonczal@hospiscript.com). The clinical information contained in this newsletter is not medical advice. Health care providers should exercise independent clinical judgment. Some information cites the use of a product in a manner or for an indication other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.
2 Continued from page 1 volume required for use of polyethylene glycol may be difficult for patients to manage. Table 2: Medications Causing Constipation 4 When stimulant and osmotic laxatives have been optimized without sufficient results, medications for refractory constipation should be considered. Table 3 lists the available prescription-only laxative medications. Methylnaltrexone (Relistor ) and naloxegol (Movantik ) are peripherally-acting µ-opioid receptor antagonists (PAMORA) that may be effective if first line agents have been exhausted. 7,8 PAMORA drugs work by blocking the activation of the µ-opioid receptors in the gastrointestinal tract while preserving the activation of µ-opioid receptors in the CNS, maintaining analgesia. 5-7 Consideration of goals of care and current swallowing status is important in determining which µ-opioid receptor antagonist to choose. Methylnaltrexone is given subcutaneously; while naloxegol s oral formulation may be desirable for some. Both methylnaltrexone and naloxegol have an onset of action of under 2 hours. 6-9 Both methylnaltrexone and naloxegol are contraindicated in patients with known or suspected bowel obstruction or for those with an increased risk of recurrent obstruction. 6 Neither will be effective if the patient is not taking opioids. Lubiprostone (Amitiza ) is a chloride channel activator that recently received FDA-approval for OIC in patients with chronic noncancer pain. Lubiprostone acts by enhancing intestinal fluid secretion and motility. 5 Results from clinical trials studying lubiprostone have been somewhat inconsistent. Improvement in constipation in the trials was measured as an increase of at least 1 spontaneous bowel movement over baseline. 9 Patients tend to report higher incidence of nausea with the higher dose of lubiprostone needed for OIC. 6 If patients cannot tolerate the 24mcg twice daily dose, the 8mcg dose is not likely to be effective for OIC and therapy should be changed. When evaluating improvement in OIC related symptoms or quality of life, at least one study found no significant difference between senna and lubiprostone. 10 Finally, Vaseline balls may be effective if a high impaction is suspected. Vaseline balls are pea-sized balls of petrolatum that are rolled in confectioner sugar, or any preferred flavored powder, and swallowed whole. 11 Because docusate is a surfactant that can emulsify mineral oil or petrolatum, discontinue all docusate containing preparations prior to use due to the risk of systemic absorption and toxicity. 11 Oral mineral oil is not recommended due to high risk of aspiration and aspiration pneumonia. 11 Opioid-induced constipation is a distressing symptom frequently experienced by hospice patients. Assessing the patient at initiation of therapy and throughout the course of treatment is imperative in early detection and treatment. Stimulant laxatives plus stool softeners remain the gold standard of treatment and doses should be maximized before adding second line therapies or other adjuvants. Newer agents, such as µ-opioid receptor antagonists, should be reserved for the management of refractory constipation. Analgesics Opioids NSAIDs Antihypertensives Calcium channel blockers Diuretics Clonidine Miscellaneous Amiodarone Cholestyramine Ondansetron Table 3: Drug Initial Dose Route Formulation Osmotic Laxatives Lactulose (Chronulac ) Methylnaltrexone (Relistor ) Naloxegol (Movantik ) Lubiprostone (Amitiza ) Prescription Medications for Constipation 30mL Daily PRN 12mg Daily PRN 25mg QAM on empty stomach Oral solution: 10g/15 ml Clinical Considerations More costly than stimulants with no improved efficacy Associated with increased cramping & flatulence Onset of action, hours Sorbitol is more cost effective, OTC equivalent product with same dosing recommendations P A G E 2 PO Anticholinergics Tricyclic antidepressants Antihistamines Antispasmodics Antipsychotics Chlorpromazine Olanzapine Prochlorperazine Quetiapine Risperidone Peripherally-acting mu-opioid receptor antagonists (PAMORA) Miscellaneous Linaclotide (Linzess ) *AWP=average wholesale price per day based on initial dosage listed. Antiepileptics Phenytoin Carbamazepine Valproate Cation-containing agents Aluminum, Calcium antacids Bismuth subsalicylate Iron supplements AWP/Day* REFERENCES: 1) Davis L. Constipation. In Protus BM, Kimbrel JM, Grauer PA, eds. Palliative Care Consultant: A Reference Guide for Palliative Care. 4th ed. Dublin, OH:HospiScript Services, ) Librach SL, Bouvette M, DeAngelis C, et al. Consensus recommendations for the management of constipation in patients with advanced, progressive illness. J Pain Symptom Manage 2010;40(5): ) O Donnell L, Virjee J, Heaton K. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990;300: ) Deepak P, Ehrenpreis E. Constipation. Dis Month 2011;57(9): ) Sharma A, Jamal M. Opioid induced bowel disease: a twenty -first century physicians dilemma. Curr Gastroenterol Rep. 2013;15:334. 6) Lexi-Comp Online. Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc. February 18, ) Leonard J, Baker D. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015;49(3): ) Rhiner M, Ferrell B, Yudin J. Opioid-induced constipation (OIC) in advanced illness patients receiving palliative care when response to laxative therapy has not been sufficient. Home Healthcare Nurse. 2009;27(1): ) Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid-induced constipation: a systematic review. Expert Opin Pharmacother. 2015;16(4): ) Marciniak C, Toledo S, Lee J, et al. Lubiprostone vs senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active comparative trial. World J Gastroenterol. 2014;20(43): ) Tavares C, Kimbrel J, Protus BM, Grauer P. Petroleum jelly (Vaseline balls) for the treatment of constipation: a survey of hospice and palliative care practitioners. Am J Hosp Palliat Med. 2014;31(8): $2.30 SC Injection: 8mg/0.4mL, 12mg/0.6mL Indicated for second line treatment of OIC, after oral stimulant laxatives and suppositories have failed Weight based dosing 0.15mg/kg Onset of action, minutes $86.50 PO Tablets: 12.5mg, 25mg Indicated for treatment of OIC in patients with chronic noncancer pain Drug interactions with CYP3A4 inducers/inhibitors Take on empty stomach at least 1 hour before or 2 hours after meal Do not crush or chew tablets Avoid grapefruit, grapefruit juice $ mcg BID PO Capsules: 8mcg, 24mcg Efficacy may be reduced by methadone Take with food to decrease nausea Indicated for chronic idiopathic constipation or OIC in chronic noncancer pain Do not chew or open capsules $ mcg Daily PO Capsules: 145mcg, 290mcg Take with food to decrease nausea Indicated only for constipation predominant IBS or chronic idiopathic constipation Do not open or chew capsules $11.10
3 Clinical Case Study: Opioid-Induced Constipation Molly Sinert, RPh, PharmD, Clinical Pharmacist, HospiScript Patient: SD, male, age 71 Hospice Diagnosis: Lung cancer, with metastases to bone Chief Complaint: Severe constipation Functional Status: Palliative Performance Scale (PPS) 40% Past Medical History: Benign Prostatic Hyperplasia (BPH), hypertension, anemia History of Present Illness: SD resides in a nursing home. He has gone 6 days without a bowel movement. He received doses of PRN milk of magnesia, followed by PRN bisacodyl (Dulcolax ) suppository 2 days ago. Manual disimpaction today was unsuccessful. SD has reduced oral intake of foods and fluids, but has been compliant with all routine medications, including his bowel regimen, linaclotide (Linzess ) and senna (Senokot ). The nursing home physician has discontinued linaclotide and senna with new orders for methylnaltrexone (Relistor ) 12mg subcutaneous daily until the patient has a bowel movement, then start lubiprostone (Amitiza ) 24mcg PO BID for opioid-induced constipation. Allergies: Penicillin (hives) Current Medications: Acetaminophen (Tylenol ) 325mg 1-2 tablets PO q4h prn mild pain or fever Acetaminophen/Codeine (Tylenol #3 ) mg 1 tablet PO q4h prn moderate to severe pain Bisacodyl (Dulcolax ) 10mg 1 suppository rectally as needed if no result from milk of magnesia Esomeprazole magnesium (Nexium 24 HR ) 22.3mg PO every morning Ferrous sulfate 325mg 1 tablet PO BID Finasteride (Proscar ) 5mg 1 tablet PO daily Hydrochlorothiazide (Microzide ) 25mg 1 tablet PO daily Linaclotide (Linzess ) 145mcg 1 capsule PO daily Lisinopril (Zestril ) 5mg 1 tablet PO daily Milk of magnesia 400mg/5mL, take 30mL PO daily prn constipation Morphine ER (MS Contin ) 15mg 1 tablet PO q12h Naproxen (Naprosyn ) 250mg 1 tablet PO q8h ATC Promethazine (Phenergan ) 25mg 1 tablet PO q6h prn nausea/vomiting Senna (Senokot ) 8.6mg 1 tablet PO BID Tamsulosin (Flomax ) 0.4mg 1 capsule Po daily Pharmacist consultation with the nurse revealed the following: Patient is mainly bed bound and has no trouble swallowing pills BP 136/78 mmhg, pulse 86; no signs of edema Bowel sounds hypoactive Disimpaction was unsuccessful, as RN was only able to scrape off some stool Patient denies nausea/vomiting, but states his belly feels full and that is why he does not eat or drink as much There is recent evidence of dehydration (skin is dry and pulse is higher than normal) Pain has increased all over, so the patient started using more PRN acetaminophen/codeine about 2 weeks ago; prior to that he required only one dose a week on average Linaclotide was started 3 weeks ago, because the patient has had ongoing trouble with constipation Patient has been on Senna 1 tablet PO BID since he started Morphine ER (before hospice admission) Patient refuses enema due to past use resulting in residual diarrhea; type of enema unknown Medication points of discussion: Review all potential causes of constipation, including medications for this patient. Evaluate risk vs benefit of medications that may be contributing to constipation to guide decision-making about the need to continue these medications. Although opioids cause constipation, most patients continue opioid therapy for pain and dyspnea management. In order to provide analgesic effects, codeine requires metabolism to morphine. Some patients may have reduced ability to metabolize codeine, impairing efficacy but still exposing them to side effects like constipation. 1 Optimizing adjuvant analgesics may reduce total opioid intake, thus reducing risk of constipation. Oral corticosteroids can help manage pain related to the patient s bone metastases. 2 Ferrous sulfate is associated with constipation, dark stools, and GI upset, and does not offer palliative benefit making it easy to discontinue without sacrificing comfort. 3 Blood pressure, edema, and hydration status should be regularly assessed, with prompt discontinuation of diuretics when clinically indicated (i.e. hypotensive, no edema present, dehydration). Immobility and dehydration can lead to fecal impaction and bowel obstruction, especially in elderly patients. 4,5 Patient has denied nausea and vomiting; there was no mention of new or significant abdominal pain or cramping, therefore low suspicion of bowel obstruction. Fecal impaction is likely high in the rectum or in the colon based on difficulty reaching stool for manual disimpaction. High impactions can be treated with Vaseline balls. 6 Vaseline balls are frozen pea-sized balls of white petrolatum coated with a powder for taste (cocoa powder, fruit juice powder, powdered sugar). They function to lubricate the lower GI passageway and soften the stool. Discontinue docusate-containing products during therapy with Vaseline balls. Although methylnaltrexone and lubiprostone are approved to treat opioid induced constipation, they are not first-line options 3 Stimulant laxatives can overcome reduced intestinal motility caused by opioids, and the addition of a stool softener can make it easier for stool to pass. 7 Senna (stimulant) and docusate (stool softener) is the preferred first-line regimen to manage opioid-induced constipation. 8 Consider osmotic laxatives if additional therapy is needed once senna and docusate are optimized. Sorbitol is more cost effective than lactulose although palatability may be difficult with either sorbitol or lactulose. 8 Reserve methylnaltrexone or lubiprostone as second-line therapy if the patient has not responded to preferred treatments and all causative factors have been addressed. 8 Pharmacist and case manager agreed on the following plan to discuss with the attending physician: 1) Discontinue linaclotide as per patient s attending physician. 2) Discontinue medications contributing to constipation: ferrous sulfate, hydrochlorothiazide, and acetaminophen/codeine. 3) Non-pharmacological management: a) Encourage oral hydration and/or foods with high water content as tolerated (e.g., fruits, soups, yogurt). b) Encourage low-impact exercise as tolerated in bed or chair, or abdominal massage. 4) Acute impaction (recommend the following in place of methylnaltrexone): a) Increase plain senna to 2 tablets PO BID, then increase by 1 tablet per dose every day there is no bowel movement (maximum 4 tablets PO BID). b) Initiate Vaseline balls 3-6 balls swallowed whole daily until a bowel movement occurs. 5) Chronic prevention (recommend the following in place of lubiprostone): a) Once patient has the first bowel movement, discontinue plain senna and Vaseline balls. b) Initiate senna-docusate 2 tablets PO BID, may titrate gradually up to 4 tablets PO BID if necessary. c) If senna-docusate is not effective alone to prevent opioid-induced constipation, add sorbitol 15mL PO daily and titrate as necessary. 6) Pain management a) Replace acetaminophen/codeine with morphine immediate release (20mg/mL) 5mg PO/SL q2h prn pain or dyspnea. b) Replace naproxen with dexamethasone 4mg PO QAM to improve pain and breathing, and reduce overall opioid needs. REFERENCES: 1) Smith, HS. Opioid Metabolism. Mayo Clin Proc. 2009;84(7): ) Weinstein E, Arnold R. Steroids in the treatment of bone pain #129. J Palliat Med. 2010;13(7): ) Lexi-Comp Online. Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc. March 12, ) Librach SL, Bouvette M, DeAngelis C, et al. Consensus recommendations for the management of constipation in patients with advanced, progressive illness. J Pain Symptom Manage. 2010;40(5): ) National Cancer Institute. Gastrointestinal Complications: Impaction. National Institutes of Health. HealthProfessional/page3. March 12, ) Tavares CN, Kimbrel JM, Protus BM, Grauer PA. Petroleum jelly (Vaseline balls) for the treatment of constipation: a survey of hospice and palliative care practitioners. Am J Hosp Palliat Med. 2014;31(8): ) Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008;35: ) Davis L. Constipation. In Protus BM, Kimbrel JM, Grauer PA, eds. Palliative Care Consultant: A Reference Guide for Palliative Care. 4th ed. Dublin, OH:HospiScript Services, H O S P I S C R I P T N E W S L E T T E R V O L U M E 1 1. I S S U E P A G E 3 EMPOWERING HOSPICE CARE THROUGH INNOVATION TM
4 IN THE SPOTLIGHT Palliative Care Consultant 4th Edition The 4th Edition It s here! Order the Palliative Care Consultant 4th Edition online today, and have it shipped directly to your door. ORDER AT HospiScript.com/books REGISTER TODAY! REGISTRATION INCLUDES BOOK CHOICE Retail Price $69.99 Regional Conference VISIT FOR DETAILS Retail Price $79.99 Retail Price $24.99 May 14-15, 2015 Historic Savannah, Georgia Marriott Savannah Riverfront Special thanks to Patron Sponsor Hands of Hope, a Division of Hospice Care of South Carolina Free for HospiScript Clients Free Publication Choice PCC 4th Edition, Pediatric PCC or Wound Care Adult & Pediatric Sessions Free Continuing Education Credits P A G E 4
5 Lunch & Learn Teleconference Programs Schedule Enhancing Patient Care through Education Register Online Today! HospiScript strives to meet your educational needs. Every month, HospiScript hosts teleconferences on topics of special interest to hospice staff. All HospiScript clients are encouraged to participate free of charge. Continuing Education Credits are also available for a nominal processing fee. To register, please visit and click on the Educate, Event Registration link. MAY 2015 JUNE 2015 JULY 2015 Navigating the Market: New Medications & Implications for Hospice & Palliative Care Stacey Rexrode, PharmD, CGP; HospiScript Wednesday 05/06/15 3:00 PM ET Thursday 05/07/15 10:00 AM ET Don t Lose Sleep Over It! Medication Management in Sleep Disturbances in End of Life Care Elizabeth Miles, PharmD; HospiScript Wednesday 06/03/15 3:00 PM ET Thursday 06/04/15 10:00 AM ET Don t Let the Management of Depression at the End of Life Get You Down Marliese Gibson, PharmD; HospiScript Wednesday 07/01/15 3:00 PM ET Thursday 07/02/15 10:00 AM ET Caring Across Cultures: Providing Healthcare to Diverse Patients & Families Donna Skurzak, MA, LSW, CDP; Cleveland Clinic Wednesday 05/20/15 3:00 PM ET Thursday 05/21/15 10:00 AM ET Live Discharges: The Regulations with Case Studies Jennifer Kennedy, RN, MA, BSN, CHC; National Hospice & Palliative Care Organization (NHPCO) Wednesday 06/17/15 3:00 PM ET Thursday 06/18/15 10:00 AM ET My Brother s Keeper: Caring for Vulnerable Patients at the End of Life Jean O Leary-Pyles, BASW, MSW, LISW-S; OhioHealth Hospice Wednesday 07/22/15 3:00 PM ET Thursday 07/23/15 10:00 AM ET CLINICIAN S CORNER: Hospice Item Set (HIS): NQF 1617 Patients Treated with an Opioid who are Given a Bowel Regimen Bridget McCrate Protus, RPh, PharmD, MLIS, CGP, CDP, Director of Drug Information, HospiScript Opioids are commonly used for management of moderate to severe pain; constipation is a common opioid adverse effect. Clinical studies demonstrate that opioid-related constipation is a significant problem in adults of all ages using opioids for cancer-related pain or chronic non-cancer pain. 1 Severe constipation may cause patients to access hospital emergency departments even in the last 6 months of life. 2 Tolerance to the constipating effects of opioids is not developed; therefore, preventive laxative therapy is necessary for most patients. 1 Additionally, patients in hospice care frequently have limited mobility and dehydration, further contributing to the risk of constipation. Centers for Medicare & Medicaid Services (CMS) and the National Quality Forum (NQF), as well as other patient advocacy organizations, consider effective symptom management to be a hallmark of quality hospice care. Hospices are now required to report data for patient admissions for 7 quality measures, also known as the Hospice Item Set (HIS). These include measures on screening and assessment of pain and dyspnea, preferences for life sustaining treatment, discussion of religious/spiritual concerns, and patients treated with opioids who are prescribed a bowel regimen. The quality measure concerning opioids and bowel regimens (NQF 1617) describes the percentage of adult hospice patients treated with an opioid that are offered or prescribed a bowel regimen. 3,4 To meet this quality measure, when opioids are initiated, orders for a bowel regimen should be in place unless there is documentation in the patient s chart that a bowel regimen is not needed. CMS has clarified that comfort care kits including opioids, delivered to the patient s home, are considered on standby and not initiated until the hospice instructs the patient or caregiver to begin using the treatment for the relevant symptom. 5 Patients with standby orders for opioids are not included in the NQF 1617 measure; in other words, orders for a bowel regimen are not required until the patient actually begins using the opioid. CMS has not yet determined what the benchmark percentage indicator will be for NQF Based on patient medication profiles, just over 77% of patients cared for by HospiScript partners have both an opioid and a laxative in place. We recommend incorporating the HospiRxMonitor report, Opioids No Laxatives into your patient discussions during your interdisciplinary group meetings. Contact your account manager for assistance in accessing HospiRxMonitor. For more information on HIS requirements, please visit the Hospice Item Set (HIS) portion of the CMS Hospice Quality Reporting Program website at Instruments/Hospice-Quality-Reporting/. REFERENCES: 1) McNicol E, Horowicz-Mehler N, Fisk R, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4(5): ) Barbera L, Taylor C, Dudgeon D. Why do patients with cancer visit the emergency department near the end of life? CMAJ 2010;186(2): Available at pmc/articles/pmc /pdf/ pdf. 3) Centers for Medicare & Medicaid Services (CMS). Hospice Quality Reporting. Hospice Item Set (HIS). Current Measures. Baltimore, MD: CMS, 03/09/2015. Available at Reporting/Current-Measures.html. Accessed March 16, ) National Quality Forum (NQF). Patients treated with an opioid who are given a bowel regimen (Rand). Washington, DC: National Quality Forum, 04/17/2014. Available at forum.org/qps/qpstool.aspx. Accessed March 16, ) Centers for Medicare & Medicaid Services (CMS). Hospice Item Set (HIS): Quarterly Questions and Answers. October Baltimore, MD: CMS, 02/18/2015. Available at Quality-Reporting/Hospice-Item-Set-HIS.html. P A G E 5
6 Communications is a key element in how HospiScript informs you about educational information, special programs and important news alerts. We want to hear from you! You can take the survey by visiting Ask HospiScript The Ask HospiScript column shares information and updates about the HospiScript program for our clients. Please forward your comments or questions to info@hospiscript.com. Does HospiScript provide an e-prescribing solution? e-prescribing Solution Yes. HospiScript has teamed up with DrFirst to offer their state-of-theart e-prescribing solution to HospiScript clients. DrFirst and HospiDirect allow nurses to notify physicians of prescription needs while allowing physicians the convenience of prescribing from anywhere! No more emergency fills. No more locating a fax machine in the middle of the night. The efficiency of electronic medication orders streamlines the processes saving time and money. HospiScript understands the unique challenges our hospice clients face with ever changing regulations and, the having to do more with less reality. We are delighted to offer this easy to use, award winning software to our hospice clients at a reduced rate. Please contact your Account Manager for more information. P A G E 6
daily; available as 10- mg g PO
Overview of the PRN: The Pain and Palliative Care PRN of ACCP is an organization of pharmacy practitioners, clinical scientists, pharmacy educators, and others. Its mission is to advance pain and palliative
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Symproic GENERIC NAME Naldemedine MANUFACTURER Shionogi Inc. DATE OF APPROVAL March 23, 2017 PRODUCT LAUNCH DATE Anticipated to launch mid-summer 2017 REVIEW TYPE Review type 1 (RT1): New Drug
More informationConstipation an Old Friend. Presented by Dr. Keith Harris
Constipation an Old Friend Presented by Dr. Keith Harris Irregularity and the Tricks of the Trade." CONSTIPATION What is constipation? INFREQUENT BOWEL MOVEMENTS DIFFICULTY DURING DEFECATION SENSATION
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 2Q17 April May
BRAND NAME Trulance GENERIC NAME Plecanatide MANUFACTURER Synergy Pharmaceuticals, Inc. DATE OF APPROVAL January 19, 2017 PRODUCT LAUNCH DATE Anticipated in 1Q2017 REVIEW TYPE Review type 1 (RT1): New
More informationPharmacy Benefit Determination Policy
Policy Subject: Opioid Induced Constipation Policy Number: SHS PBD11 Category: GI Agents Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS
More informationWhat Is Constipation?
CONSTIPATION What Is Constipation? Constipation is when you have infrequent or hard-to-pass bowel movements (meaning they are painful or you have to strain), have hard stools or feel like your bowel movements
More informationOpioid constipation treatment dulcolax
P ford residence southampton, ny Opioid constipation treatment dulcolax Posts about how to relieve constipation instantly written by gbrese1958. Official Web site for MOVANTIK (naloxegol) tablets, for
More informationAmitiza. Amitiza (lubiprostone) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.22 Subject: Amitiza Page: 1 of 5 Last Review Date: March 16, 2018 Amitiza Description Amitiza (lubiprostone)
More informationDrugs Affecting the Gastrointestinal System. Antidiarrheal and Laxatives
Drugs Affecting the Gastrointestinal System Antidiarrheal and Laxatives Diarrhea Abnormal frequent passage of loose stools or Abnormal passage of stools with increased frequency, fluidity, and weight,
More informationAntidiarrheals Antidiarrheal
Antidiarrheals Major factors in diarrhea Increased motility of the GI tract. Decreased absorption of fluid. Antidiarrheal drugs include: Antimotility agents. Adsorbents. Drugs that modify fluid and electrolyte
More informationConstipation. Self-study course
Constipation Self-study course 2 Course objectives: At the end of this course you will be able to: 1. Define the term constipation 2. Explain three reasons why older adults are at greater risk for constipation
More informationUnderstanding & Alleviating Constipation. Living (Well!) with Gastroparesis Program Warm-Up Class
Understanding & Alleviating Constipation Living (Well!) with Gastroparesis Program Warm-Up Class Please Remember The information presented is for educational purposes only and is in no way intended as
More informationConstipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment
CONSTIPATION Constipation An Overview Definition Physiology of GI tract Etiology Assessment Treatment Definition Constipation = the infrequent passage of hard feces Definition of Infrequent The meaning
More informationOPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES
OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES Introduction Introduction Mean faecal weight 128 g / cap / day Mean range 51-796 g Absolute range 15-1505 g Main factors affecting mass are caloric intake,
More informationPrimary Care Constipation Guidelines. Version 1 November 2016
Primary Care Constipation Guidelines Version 1 November 2016 VERSION CONTROL Version Date Amendments made Version 1 November 2016 New guideline Contents 1. Management of constipation in adults: acute and
More informationConstipation. What is constipation? What is the criteria for having constipation? What are the different types of constipation?
What is constipation? is defined as having a bowel movement less than 3 times per week. It is usually associated with hard stools or difficulty passing stools. You may have pain while passing stools or
More informationOpioid-Induced Constipation
Objectives Opioid-Induced Constipation Brianna Jansma, PharmD Alex Smith, PharmD Megan Robinson, PharmD Summarize epidemiology of opioid-induced constipation (OIC) Understand opiates effects on the gastrointestinal
More informationA patient s guide to the. management of constipation following surgery
A patient s guide to the management of constipation following surgery This leaflet has been designed to give you more information about using laxatives after your surgery. What is constipation? After your
More informationSYMPROIC (naldemedine tosylate) oral capsule
SYMPROIC (naldemedine tosylate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationTreatment of Constipation in Adults
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330407 Treatment of Constipation in Adults Use this document as a stepwise
More informationProtectives and Adsorbents. Inorganic chemistry Course 1 Third year Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry
Protectives and Adsorbents Inorganic chemistry Course 1 Third year 2016-2017 Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry Protectives and Adsorbents This group of gastrointestinal agents
More informationEfficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club
Efficacy and Safety of Lubiprostone Laura Wozniak February 23, 2010 K30 Monthly Journal Club Objectives Brief overview of constipation Review of article Discussion Constipation in Children 3-5% of all
More informationElderly Man With Chronic Constipation
Elderly Man With Chronic Constipation Linda Nguyen, MD Director, Neurogastroenterology and Motility Clinical Assistant Professor Stanford University Overview Normal bowel function Defining Constipation:
More informationRelief, true to form
For adults with Chronic Idiopathic Constipation (CIC) or Irritable Bowel Syndrome with Constipation (IBS-C) Relief, true to form When It Comes to Constipation Relief, Form Matters Trulance can help you
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationClass Review: Drugs for Constipation
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 4 Cathartics. LESSON ASSIGNMENT Paragraphs 4-1 through 4-10. LESSON OBJECTIVES After completing this lesson, you should be able to: 4-1. Given a group of statements, select the
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 7 Last Review Date: November 30, 2018 Opioid Antagonist
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Relistor) Reference Number: CP.CPA.274 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationAttach patient label here. Physician Orders ADULT: Palliative Care Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Palliative Care Phase, When to Initiate: Palliative Care Phase Admission/Transfer/Discharge Patient Status Initial
More informationRevisionary Capsulorrhaphy Surgery Aftercare Guidelines Following Day Date:
Surgery Sleep in a reclined positon Medications- take as directed Soft Diet and liquids Stool softener/high Fiber foods Leave on all dressing Surgical Stockings First Night Revisionary Capsulorrhaphy Surgery
More informationBreast Augmentation Saline Overfilled Surgery Aftercare Guidelines
Surgery Breast Augmentation Saline Overfilled Surgery Aftercare Guidelines First Night Following Day 3-5 Days 1 st Post op Visit 7-10 Days 2 nd Post op Visit 2 Weeks Post op 4-6 Weeks Post op 8-12Weeks
More informationAdjustable Gastric Band Surgery Discharge Instructions
Columbia University Center for Metabolic and Weight Loss Surgery Columbia University Medical Center The Herbert Irving Pavilion 161 Fort Washington Ave, 5 th floor, Room 524 New York, New York 10032 Health
More informationConstipation and bowel obstruction
Constipation and bowel obstruction Constipation Infrequent or difficult defecation with reduced number of bowel movements, which may or may not be abnormally hard with increased difficulty or discomfort
More informationLiquaFiber Clinical Trial
LiquaFiber Clinical Trial Effects of Dietary Fiber LiquaFiber - on Replacing Bowel Medications and Psyllium Fiber use in Long Term Care Residents This clinical trial was performed at Monroe Community Hospital
More informationUsing Evidence Based Medicine to Ethically Provide End of Life Symptom Control
Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control Erin Zimny, MD Emergency Medicine Hospice and Palliative Medicine Henry Ford Hospital Disclosures I do NOT have any financial
More informationNavigating the Road to Efficient Medication Use
Navigating the Road to Efficient Medication Use Molly R. Sinert, RPh, PharmD Clinical Pharmacist HospiScript Services LLC a Catamaran Rx Company October 28, 2013 Objectives Describe the components of the
More informationABC s of Bowel Management
ABC s of Bowel Management Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, 2018 Eric Levey, M.D. Pediatrics & Neurodevelopmental Disabilities Chief Medical
More informationSymptom Management Challenges at End-of-Life
Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify
More informationOpioid Use in Palliative Care
Opioid Use in Palliative Care Relief of pain is one of the core components of palliative care 1,2 Up to 69% of patients with advanced cancer experience pain 3 ~65% of patients dying from nonmalignant disease
More informationFOOT OFF THE BRAKES. Kerri Novak MD MSc FRCPC. Chronic Constipation: Taking the Foot off the Brakes Dr. Kerri Novak
CHRONIC CONSTIPATION: TAKING THE FOOT OFF THE BRAKES Kerri Novak MD MSc FRCPC www.seacourses.com 1 OUTLINE Epidemiology i Quality of life Approach Therapies www.seacourses.com 2 DEFINING CHRONIC CONSTIPATION
More informationGastric Bypass, Banded Gastric Bypass and Sleeve Gastrectomy Surgery Discharge Instructions
Columbia University Center for Metabolic and Weight Loss Surgery Columbia University Medical Center The Herbert Irving Pavilion 161 Fort Washington Ave, 5 th floor, Room 524 New York, New York 10032 Health
More informationAdvances in Palliative Care
Steven Pantilat, MD Professor of Clinical Medicine Alan M. Kates and John M. Burnard Endowed Chair in Palliative Care Director, Palliative Care Program and Palliative Care Leadership Center Division of
More informationOpioids: Safe Use and Side Effects
Opioids: Safe Use and Side Effects Your doctor has prescribed an opioid (OHpee-oyd). This drug can control moderate to severe pain without increased risk of bleeding and kidney problems. Always take the
More informationUnderstanding your take home medications from the surgical ward. Information for Patients
Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for
More informationAging Persons with Intellectual Developmental Disorders (IDD): Constipation KEYPOINTS OVERVIEW
Aging Persons with Intellectual Developmental Disorders (IDD): Constipation KEYPOINTS A major medical conditions that commonly is seen among persons with IDD and may lead to serious complications is constipation.
More informationOpioid-induced constipation a preventable problem
www.veteransmates.net.au Opioid-induced a preventable problem One of the most common adverse effects of chronic opioid therapy is. 1-4 Up to 95% of patients prescribed an opioid report as a side effect,
More informationAgitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety.
October 2012 4 Agitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety. Depending on appropriateness, evaluate for reversible
More informationIdentify electrolytes that should be monitored whenever prolonged or severe diarrhea is present
Chapter 35 Drugs Used to Treat Constipation and Diarrhea Learning Objectives State the underlying causes of constipation Explain the meaning of normal bowel habits Cite nine causes of diarrhea Describe
More informationMANAGING CONSTIPATION
MANAGING CONSTIPATION INFORMATION FOR OLDER ADULTS, FAMILIES, AND CAREGIVERS READ THIS PAMPHLET TO LEARN: What Constipation is. The Symptoms of Constipation. How to Help Manage Constipation. WHAT IS CONSTIPATION?
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationThe Road to Opioid-Induced Constipation: Pathophysiology and Impact Kenneth C. Jackson, II, PharmD, CPE
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of March 2015. The content and views presented in this educational activity are those of the
More informationPOOP: WHAT S NORMAL & WHAT S NOT
HEALING LEAKY GUT POOP: WHAT S NORMAL & WHAT S NOT Is my poop normal? Most of us have asked ourselves that at one time or another. When your poop isn t right, it definitely indicates something isn t quite
More information3.4 gram/7 gram powder -- $5.63
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Bowel Movements P&T DATE: 9/11/2018 CLASS: Gastrointestinal Disorders REVIEW HISTORY: 12/16, 9/15, 9/12, 5/08 LOB: MCL (MONTH/YEAR)
More information(30689) PROT Pain PCA Adult Patient Controlled Analgesia
Diagnosis Allergies Nursing Assess and Document PCA: 1. Assess and document pain rating, sedation level and respiratory rate every 2 hours; assess and document pain rating, sedation level and respiratory
More informationACTIVITY DESCRIPTION FACULTY. Opioid Use in Palliative Care. Opioid Analgesic Use in Chronic, Non-cancer Pain
ACTIVITY DESCRIPTION Target Audience This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems,
More informationConstipation and Other Gastrointestinal Problems in PD
Living with PD Constipation and Other Gastrointestinal Problems in PD As you know, Parkinson s disease (PD) affects many body systems, not just movement. This includes the autonomic nervous system that
More informationConstipation. Myeloma Infosheet Series. Symptoms and complications. Infoline:
Constipation This Infosheet explains what constipation is, what causes it in myeloma patients, what the symptoms of it are, how it is treated and some tips for self-management. What is constipation? Constipation
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS. Version 1 (reviewed unchanged January 2018)
GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS Version 1 (reviewed unchanged January 2018) RATIFYING COMMITTEE Drugs and Therapeutics Group DATE ORIGINALLY 29 th October2014
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 5 Last Review Date: December 2, 2016 Opioid Antagonist
More informationDOCTOR DISCUSSION GUIDE
What your doctor needs to know To make your appointment more productive, share this completed guide with your doctor. That way, he or she can recommend an appropriate treatment plan for you. Check the
More informationOpioid Induced Constipation Lisa Clince Acute Pain CNS Palmerston North Hospital
Opioid Induced Constipation Lisa Clince Acute Pain CNS Palmerston North Hospital 21-04-2016 MidCentral District Health Board 1 Overview Patient Experience Opioid Collaborative Constipation defined Opioid
More informationRELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE
RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for
More informationPurchase (over the counter):
. COLONOSCOPY PREPARATION LOCATION: SOUTHDALE MEDICAL CENTER Appointment Date: Time: 6545 FRANCE AVE S. SUITE 290 EDINA, MN 55435 You are scheduled for a colonoscopy, a procedure in which a doctor examines
More informationBROOKSIDE WELLNESS COLON HYDROTHERAPY INTAKE FORM 504 Shartom Drive Augusta, Georgia
BROOKSIDE WELLNESS COLON HYDROTHERAPY INTAKE FORM brooksidewellness@me.com 504 Shartom Drive Augusta, Georgia 30909 706-922-6710 Date First Name: M.I. Last Name: Email: Mobile number: Emergency contact
More informationManagement of the Neurogenic Bowel. June st National SBAA Conference Bloomington, Minnesota
Management of the Neurogenic Bowel June 2016 41st National SBAA Conference Bloomington, Minnesota DEPARTMENT OF NURSING Rhonda Bolin, BSN, RN, CPN Spina Bifida Nurse Texas Children s Hospital Spina Bifida
More informationColonoscopy Bowel Prep Instructions Miralax /Gatorade
Colonoscopy Bowel Prep Instructions Miralax /Gatorade Refer to this instruction sheet for the entire week before your colonoscopy. Colonoscopy prep instructions are extremely important for a successful
More informationPatient information: Constipation in adults
Page 1 of 9 Official reprint from UpToDate www.uptodate.com 2011 UpToDate Patient information: Constipation in adults Author Arnold Wald, MD Section Editor J Thomas LaMont, MD Deputy Editor Anne C Travis,
More informationManaging Care at End of Life:
Managing Care at End of Life: Physical Suffering Pain & Dyspnea Verna Sellers, MD, MPH, AGSF Medical Director Centra PACE Lynchburg, Virginia 1 Speaker Disclosures: Dr. Sellers has disclosed that she has
More informationHome Care Instructions. Cervical Laminoplasty
Home Care Instructions Cervical Laminoplasty You are recovering from a posterior cervical decompression in which your surgeon removed the pressure on your spinal nerves in an attempt to reduce pain and/or
More informationGuidelines for Management and Prevention of Delirium In Geriatric Trauma Patients
Guidelines for Management and Prevention of Delirium In Geriatric Trauma Patients Objectives: Provide a guideline for recognizing and managing delirium in geriatric trauma patients. Provide a template
More informationPreparing For Colonoscopy
Preparing For Colonoscopy COLONOSCOPY OVERVIEW A colonoscopy is an exam of the lower part of the gastrointestinal tract, which is called the colon or large intestine (bowel). Colonoscopy is a safe procedure
More informationConstipation a symptom NOT a disease! Bowels/Constipation Documentation The A-B-C-D. Documentation: Bowels/Constipation
Documentation The A-B-C-D Terry Broda, RN(EC), BScN, NPHC,CDDN Elizabeth Kacew, RN(EC), MScN, NP-PHC October 30, 2014 Constipation a symptom NOT a disease! 1 How serious a problem? 50-85% of older people
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 RELISTOR 12 mg/0.6 ml solution for injection 1 vial (CIP: 387 365-1) 2 vials + 2 sterile syringes
More informationPeristeen and the Neurogenic Bowel Dysfunction Score (NBD) for pediatric patients with spina bifida
Peristeen and the Neurogenic Bowel Dysfunction Score (NBD) for pediatric patients with spina bifida Coloplast develops products and services that make life easier for people with very personal and private
More informationOpen to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level
If you have multiple myeloma and have already tried at least 2 other types of treatment Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level What is
More informationProtocol to support reducing the use of and the effective use of laxatives. HaRD CCG employed Pharmacists and Medicines Optimisation Technicians.
NY&AWC Medicines Management Team Protocol to support reducing the use of and the effective use of laxatives Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationThe 3 P s (Pain, Poop, Physical Therapy) for Post-Op Spinal Fusions
The 3 P s (Pain, Poop, Physical Therapy) for Post-Op Spinal Fusions Pain control is a key part of your care after surgery. It can help speed recovery and improve the results of your surgery. This handout
More informationSymptom Management. Dr Rosalie Shaw
Symptom Management Dr Rosalie Shaw Thank you for inviting me The story of Shariffha The goals of palliative care To relieve suffering To ensure normal functioning in daily life for as long as possible
More informationActive ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate.
NAME OF THE MEDICINE KLYX Enema Active ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate Sorbitol C20H37NaO7S MW: 444.56 CAS no: 577-11-7
More informationPreparing for your Colonoscopy Procedure
Preparing for your Colonoscopy Procedure Thank you for choosing the Gastroenterology Associates at Mass General Hospital for your colonoscopy. We want to make sure your procedure goes as smoothly as possible.
More informationLearning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016
Terminal Restlessness Dr. Christopher Churchill St. Cloud VA Health Care System EC&R Service Line Director & Medical Director Hospice & Palliative Care March 31, 2016 Learning Objectives Different Terminology
More informationDulcolax Tablets and Dulcolax Suppositories Bisacodyl
Consumer Medicine Information Tablets and Suppositories Bisacodyl What is in this leaflet 1. What is used for 2. Before you use a) When you must not use b) Before you start to use c) Pregnancy d) Breastfeeding
More informationOpioid-Induced Constipation: Update on Prevention and Management EDUCATIONALPROGRAM
EDUCATIONALPROGRAM Recognizing i the Growing Burden of OIC Bill H. McCarberg, MD Founder, Chronic Pain Management Program Kaiser Permanente San Diego Adjunct Assistant Clinical Professor University of
More informationAre you aware there are many different reasons for having irregular bowels? This chart is to help you get back into balance during and post detox.
BRISTOL POOP CHART The Bristol Poop Chart was created in the United Kingdom by a group of gastroenterologists at the University of Bristol. This chart is designed to help you determine the health of your
More informationDrug Therapy Following Bariatric Surgery
Drug Therapy Following Bariatric Surgery Linda F. McElhiney PharmD, RPh, MSP, FIACP, FACA, FASHP, DPLA Compounding Pharmacist Indiana University Health Disclosures Dr. McElhiney declare(s) no conflicts
More informationDischarge Instructions for Duodenal Switch and Distal Gastric Bypass Surgeries
Col Columbia University Center for Metabolic and Weight Loss Surgery Columbia University Medical Center The Herbert Irving Pavilion 161 Fort Washington Ave, 5 th floor, Room 524 New York, New York 10032
More informationBowel Function After Spinal Cord Injury
Bowel Function After Spinal Cord Injury A resource for individuals with SCI and their supporters This presentation is based on SCI Model Systems research and was developed with support from the National
More informationNursing Principles & Skills II. Bowel Sounds Constipation Fecal Impaction
Nursing Principles & Skills II Bowel Sounds Constipation Fecal Impaction Bowel Sounds Definitionthe noise or sounds made by the peristaltic waves of the intestinal muscle contracting and relaxing Bowel
More informationADJUSTABLE GASTRIC BAND Home Care Instructions
ADJUSTABLE GASTRIC BAND Home Care Instructions These instructions are to help you care for yourself when you go home. Call: If you have any problems. Call 336-387-8100 and ask for the surgeon on call If
More information1 of 5. Integrated Order Set Inpatient, Adult. Gynecological Surgery Enhanced Recovery Orders apply to patients 18 years and older.
Orders apply to patients 18 years and older. All preprinted doses are based on normal renal and hepatic function and must be assessed for adjustment against the individual patient s renal and hepatic function
More informationReference ID:
MEDICATION GUIDE CLENPIQ (CLEN-pik) (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution Read and understand these Medication Guide instructions at least 2 days before your colonoscopy
More informationPharmacology. Drugs that Affect the Gastrointestinal System
Pharmacology Drugs that Affect the Gastrointestinal System Topics Peptic Ulcer Disease Constipation Diarrhea Emesis Digestion Peptic Ulcer Disease Factors that Increase Acidity Factors that Protect Against
More informationAfter Your Bariatric Surgery
After Your Bariatric Surgery Information for patients and families Read this information to learn: what problems to look out for how to care for yourself at home about your follow-up appointment who to
More informationConstipation. AL amyloidosis Infosheet Series. Symptoms and complications. Infoline:
Constipation This Infosheet explains what constipation is, what causes it in AL amyloidosis patients, the signs and symptoms, how it is treated and tips for self-management/prevention. What is constipation?
More informationTo Cover or Not To Cover? A Review of Medication Coverage Guidelines. Dr. Sherita D. Castille, Pharm D Clinical Pharmacist. Agenda.
To Cover or t To Cover? A Review of Medication Coverage Guidelines Dr. Sherita D. Castille, Pharm D Clinical Pharmacist Agenda 2 Overview Define key Medicare terms Determine relatedness to terminal prognosis
More informationMedication Safety Presentation
Appendix E Aid 1: Sample Event Poster Medication Safety Presentation Do YOU know your role on the healthcare team? Do YOU know the questions to ask your pharmacist? Do YOU know safe medication practices?
More informationOral Methylnaltrexone for the. Constipation in Patients with Chronic Non-cancer Pain
Oral Methylnaltrexone for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Richard L. Rauck, 1 John F. Peppin, 2 Robert J.Israel, 3 Jennifer Carpenito, 3 Jeffrey Cohn,
More informationClient Nutrition Intake Form
Client Nutrition Intake Form Date Information Name Age Address Phone (home) Phone (cell) Email Referred by MD/Other Health care practitioner info Stats Height Current Weight Ideal Weight Weight 1 Year
More information